CaseBioscience Unites ART with CGT: Integrating Assisted Reproductive Technology (ART) and Cell & Gene Therapy (CGT) for Unmatched Quality and Performance

October 2024 – CaseBioscience is pioneering a transformative approach to biotechnology by merging the clinical success of Assisted Reproductive Technology (ART) with advancements in Cell & Gene Therapy (CGT). This innovative platform integrates decades of expertise in both fields to create groundbreaking culture media and biosolutions that address key challenges in ART and CGT.

At the core of CaseBioscience’s mission is a commitment to quality and excellence. An ISO 13485:2016 certified and FDA-registered company, CaseBioscience adheres to a rigorous quality management system that ensures all products meet the evolving standards of CGT. The company sources the highest quality ingredients as defined by ISO 20399:2022, delivering chemically defined, animal-free solutions with the lowest endotoxin levels on the market—essential for optimal outcomes in ART, where embryo preservation and success are paramount.

“Our leadership team brings decades of experience in ART, and we are applying this expertise to CGT, ensuring our solutions exceed expectations in both fields,” says the management team.

One of the company’s flagship products, CaseCryo NON-DMSO, offers unparalleled cryopreservation of pluripotent stem cells and other human cell types, setting a new standard in clinical-grade solutions. Additionally, CaseBioscience is developing next-generation culture media optimized for pluripotent stem cell metabolism, focusing on enhanced functionality, DNA stability, and clinical applicability.

The cross-pollination between ART and CGT goes both ways. CaseBioscience is leveraging its expertise in cryobiology and embryo culture methods, refined over decades in ART, to inform the development of innovative CGT solutions. This includes optimized cryopreservation techniques and enhanced culture systems aimed at improving cell survival and performance.

While ART has seen fewer innovations in recent years, CaseBioscience is committed to advancing the field by applying emerging findings from CGT and stem cell science. The company is developing safer, more effective embryo culture media, driven by scientific breakthroughs in both human and animal reproductive sciences.

By following cGMP principles, ISO standards, and extensive quality control measures, CaseBioscience ensures consistent performance across all its solutions. “Our commitment to quality and innovation sets us apart and empowers scientists and clinicians in both CGT and ART,” says the company.

In summary, CaseBioscience is uniting the best practices of ART with the innovations of CGT to drive the future of biosolutions. With a focus on quality, safety, and efficacy, the company is leading the charge in shaping the future of both fields.